City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation



Border Border
  
Click here to login to Secure Web Site   (authorized users only)  
  
Search results:  407  Clinical trial(s) found  (Page 1 of 17 )
Results per page: 25 50 100 All 1-25 Trials Jump to page:

The following studies are available for :
COH Protocol Number: 17496

Principal Investigator: Benjamin Djulbegovic, MD
Sponsor: NCI Approved External Peer Review

Title:  Evaluation of the Group Decision-making Process of Clinical Guidelines Panels

COH Protocol Number: 17457

Principal Investigator: Sunita Patel, PhD
Sponsor: Institutional

Title:  A Feasibility Study of Lifetime Stress and Effects on the Epigenome for Late-onset Breast Cancer Risk

COH Protocol Number: 17453 ClinicalTrials.gov Number: NCT03223753

Principal Investigator: Saro Armenian, DO
Sponsor: Cooperative Group

Title:  COG ALTE1631: A Randomized Web-based Physical Activity Intervention Among Children and Adolescents with Acute Lymphoblastic Leukemia

COH Protocol Number: 17391 ClinicalTrials.gov Number: NCT03369964

Principal Investigator: L. elizabeth Budde, MD, PhD
Sponsor: Industrial

Title:  A Phase Ib Study of the Safety and Pharmacology of Atezolizumab in Combination with an Immunotherapy Agent Investigated with or Without Anti-CD20 Therapy in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

COH Protocol Number: 17386 ClinicalTrials.gov Number: NCT03318939

Principal Investigator: Karen Reckamp, MD
Sponsor: Industrial

Title:  A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1)

COH Protocol Number: 17385

Principal Investigator: Maria Hahn, PhD
Sponsor: Institutional

Title:  Development of an Epigenetic Biomarker Panel for DCIS Invasiveness

COH Protocol Number: 17378 ClinicalTrials.gov Number: NCT03033576

Principal Investigator: Kim Margolin, MD
Sponsor: Cooperative Group

Title:  SWOG S1616: A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent

COH Protocol Number: 17365 ClinicalTrials.gov Number: NCT03374085

Principal Investigator: Chatchada Karanes, MD
Sponsor: Industrial

Title:  A Phase 1 Multicenter, Open-Label Study to Assess the Safety, Pharmacokinetics and Preliminary Efficacy of CC-92480 in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

COH Protocol Number: 17345 ClinicalTrials.gov Number: NCT03199586

Principal Investigator: Vincent Chung, MD
Sponsor: Industrial

Title:  First-in-Human, Dose Finding, Open Label Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients with Advanced or Metastatic Solid Tumors (including Lymphoma)

COH Protocol Number: 17340 ClinicalTrials.gov Number: NCT03319940

Principal Investigator: Ravi Salgia, MD
Sponsor: Industrial

Title:  A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects With Small Cell Lung Cancer

COH Protocol Number: 17336 ClinicalTrials.gov Number: NCT03318562

Principal Investigator: Daneng Li, MD
Sponsor: Industrial

Title:  A Pharmacodynamic Study of Oral eFT508 in Subjects With Advanced Triple-Negative Breast Cancer and Hepatocellular Carcinoma

COH Protocol Number: 17333 ClinicalTrials.gov Number: NCT03269669

Principal Investigator: Alex Herrera, MD
Sponsor: Cooperative Group

Title:  SWOG S1608: Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma

COH Protocol Number: 17332 ClinicalTrials.gov Number: NCT03355066

Principal Investigator: Vincent Chung, MD
Sponsor: Industrial

Title:  A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects with Advanced Solid Tumors

COH Protocol Number: 17313 ClinicalTrials.gov Number: NCT02642965

Principal Investigator: Weili Sun, MD, PhD
Sponsor: Cooperative Group

Title:  COG AAML1421: A Phase 1/2 Study of CPX-351 (NSC# 775341) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children with Relapsed Acute Myeloid Leukemia (AML)

COH Protocol Number: 17311 ClinicalTrials.gov Number: NCT03057626

Principal Investigator: Saro Armenian, DO
Sponsor: Cooperative Group

Title:  COG ALTE15N2: LEAHRN (Late Effects After High-Risk Neuroblastoma) Study

COH Protocol Number: 17305

Principal Investigator: Niki Tank, MD
Sponsor: Institutional

Title:  A Pilot Study to Profile the Gut Microbiome of Breast Cancer Patients that Develop Neuropathic Pain after Paclitaxel Treatment

COH Protocol Number: 17303

Principal Investigator: Anne Reb, RN, PhD
Sponsor: Institutional

Title:  GYN Oncology Survivorship Care: A Descriptive Pilot Study

COH Protocol Number: 17293 ClinicalTrials.gov Number: NCT03035253

Principal Investigator: Marwan Fakih, MD
Sponsor: Industrial

Title:  A Phase 1b Study of Navicixizumab (OMP-305B83) Plus FOLFIRI as Second Line Therapy in Subjects with Metastatic Colorectal Cancer

COH Protocol Number: 17290 ClinicalTrials.gov Number: NCT03298516

Principal Investigator: Amandeep Salhotra, MD
Sponsor: Industrial

Title:  An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety and Tolerability of DCLL9718S in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Patients With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy

COH Protocol Number: 17277 ClinicalTrials.gov Number: NCT03267524

Principal Investigator: Virginia Sun, RN, PhD
Sponsor: Institutional

Title:  Walking for Recovery From Surgery: Pilot Study of a Prehabilitation Intervention for Older Adults with Cancer and their Family Caregivers

COH Protocol Number: 17273 ClinicalTrials.gov Number: NCT03331198

Principal Investigator: Tanya Siddiqi, MD
Sponsor: Industrial

Title:  An Open-Label, Phase 1 Safety and Phase 2 Randomized Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)

COH Protocol Number: 17270 ClinicalTrials.gov Number: NCT03157128

Principal Investigator: Karen Reckamp, MD
Sponsor: Industrial

Title:  A Phase 1 Study of Oral LOXO-292 in Adult Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity

COH Protocol Number: 17240

Principal Investigator: Anthony Stein, MD
Sponsor: Institutional

Title:  Single Patient IND for RB for the Use of AG-221 in the Treatment of AML

COH Protocol Number: 17239 ClinicalTrials.gov Number: NCT03139604

Principal Investigator: Haris Ali, MD
Sponsor: Industrial

Title:  GRAVITAS-301: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease

COH Protocol Number: 17235

Principal Investigator: Jessica Clague dehart, PhD
Sponsor: Institutional

Title:  The Effect of the "Living Well After Cancer" Program on Quality of Life and Metabolic Measures

 
Results per page: 25 50 100 All 1-25 Trials Jump to page:

 
 
  
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and gynecology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.